Cytokines sit at the crossroads of immunology, biotechnology, and therapeutic innovation. They are signaling proteins with outsized influence: modulating immune responses, orchestrating cellular communication, and increasingly becoming the backbone of modern biologics. For Contract Development and Manufacturing Organizations (CDMOs), cytokines represent both an opportunity and a challenge. They promise lucrative markets in regenerative medicine, oncology, […]
Tag: Pichia Pastoris
Precision Fermentation at Scale: What Biopharma Can Learn From Food Tech
Introduction: The Strange Mirror of Biopharma and Food Biopharma has long viewed itself as the high temple of fermentation. From the earliest recombinant insulin made in E. coli to monoclonal antibodies expressed in CHO cells, the industry has prided itself on scientific rigor, regulatory discipline, and painstaking optimization. Each bioreactor is treated like a cathedral of sterility […]
Beyond E. coli: Unlocking Non-Traditional Hosts in Biologics Manufacturing
Introduction: Why “Beyond E. coli” Matters For decades, E. coli has been the undisputed workhorse of microbial biomanufacturing. From recombinant insulin in the 1980s to a vast array of enzymes, antibody fragments, and research proteins, E. coli has set the standard for scalability, cost efficiency, and genetic tractability. Yet as the biologics landscape becomes increasingly complex—spanning full-length antibodies, […]
The Top 10 Traits a Pichia CDMO Must Master to Excel in Biologics Manufacturing
The microbial CDMO space is more competitive than ever. With Pichia (now Komagataella phaffii) gaining traction as a powerful expression system, contract development and manufacturing organizations (CDMOs) must sharpen their gameplan. Here are the top ten traits that separate a great Pichia CDMO from the rest—and a few extras to elevate performance across microbial and yeast-based […]